Literature DB >> 23622980

Antiproliferative activity of 2,3-disubstituted indoles toward apoptosis-resistant cancers cells.

Igor V Magedov1, Florence Lefranc, Liliya V Frolova, Laetitia Moreno Y Banuls, Amanda S Peretti, Snezna Rogelj, Véronique Mathieu, Robert Kiss, Alexander Kornienko.   

Abstract

Many types of cancer, including glioma, melanoma, NSCLC, among others, are resistant to apoptosis induction and poorly responsive to current therapies with propaptotic agents. We describe a series of 2,3-disubstituted indoles, which display cytostatic rather than cytotoxic effects in cancer cells, and serve as a new chemical scaffold to develop anticancer agents capable of combating apoptosis-resistant cancers associated with dismal prognoses.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23622980      PMCID： PMC3915534          DOI： 10.1016/j.bmcl.2013.03.110

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  Present and potential future issues in glioblastoma treatment.

Authors:  Florence Lefranc; Niloufar Sadeghi; Isabelle Camby; Thierry Metens; Olivier Dewitte; Robert Kiss
Journal:  Expert Rev Anticancer Ther       Date:  2006-05       Impact factor: 4.512

2.  Bulbispermine: a crinine-type Amaryllidaceae alkaloid exhibiting cytostatic activity toward apoptosis-resistant glioma cells.

Authors:  Giovanni Luchetti; Robert Johnston; Véronique Mathieu; Florence Lefranc; Kathryn Hayden; Anna Andolfi; Delphine Lamoral-Theys; Mary R Reisenauer; Cody Champion; Stephen C Pelly; Willem A L van Otterlo; Igor V Magedov; Robert Kiss; Antonio Evidente; Snezna Rogelj; Alexander Kornienko
Journal:  ChemMedChem       Date:  2012-03-02       Impact factor: 3.466

3.  Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.

Authors:  Anne Mathieu; Myriam Remmelink; Nicky D'Haene; Stanislas Penant; Jean-François Gaussin; Rob Van Ginckel; Francis Darro; Robert Kiss; Isabelle Salmon
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

Review 4.  Anti-apoptotic mechanisms of drug resistance in cancer.

Authors:  T R Wilson; P G Johnston; D B Longley
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

5.  Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.

Authors:  Fabrice Branle; Florence Lefranc; Isabelle Camby; Judith Jeuken; Anneke Geurts-Moespot; Sandra Sprenger; Fred Sweep; Robert Kiss; Isabelle Salmon
Journal:  Cancer       Date:  2002-08-01       Impact factor: 6.860

Review 6.  Why does cytotoxic chemotherapy cure only some cancers?

Authors:  Philip Savage; Justin Stebbing; Mark Bower; Tim Crook
Journal:  Nat Clin Pract Oncol       Date:  2008-11-04

Review 7.  Anoikis resistance and tumor metastasis.

Authors:  Craig D Simpson; Kika Anyiwe; Aaron D Schimmer
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Cost of migration: invasion of malignant gliomas and implications for treatment.

Authors:  A Giese; R Bjerkvig; M E Berens; M Westphal
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

10.  In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate.

Authors:  T Janssen; F Darro; M Petein; G Raviv; J L Pasteels; R Kiss; C C Schulman
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860
View more
  2 in total

1.  Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.

Authors:  Alexander V Aksenov; Alexander N Smirnov; Igor V Magedov; Mary R Reisenauer; Nicolai A Aksenov; Inna V Aksenova; Alexander L Pendleton; Gina Nguyen; Robert K Johnston; Michael Rubin; Annelise De Carvalho; Robert Kiss; Véronique Mathieu; Florence Lefranc; Jaime Correa; David A Cavazos; Andrew J Brenner; Brad A Bryan; Snezna Rogelj; Alexander Kornienko; Liliya V Frolova
Journal:  J Med Chem       Date:  2015-02-20       Impact factor: 7.446

2.  Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines.

Authors:  Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Roland E Kälin; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko
Journal:  Eur J Med Chem       Date:  2015-08-29       Impact factor: 6.514
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.